Published in Elder Law Weekly, December 21st, 2005
The antibody product was developed using Medarex's UltiMAb technology and is the first UltiMAb-derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex. Medarex also expects to receive additional milestone payments as well as royalties on any commercial sales resulting from the development of this product.
Medarex is a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.